Design and reporting modifications in industry-sponsored comparative psychopharmacology trials.
This review of recently published pharmaceutical industry-sponsored comparative psychotropic drug trials aims to classify apparent design and reporting modifications that favor the sponsor's product. The modifications have been grouped into 13 discrete categories, and representative examples of each are presented. Strong circumstantial evidence suggests that marketing goals led to these adjustments. The consequences of marketing influences on comparative psychopharmacology trials are discussed in terms of conflicts of interest, the integrity of the scientific literature, and costs to consumers, as well as their impact on physician practice.
D002985:Clinical Protocols / Q000592:standards; D002986:Clinical Trials as Topic / Q000191:economics / Q000379:methods / Q000592:standards*; D003219:Confidentiality; D004334:Drug Administration Schedule; D016527:Drug Costs / Q000592:standards; D004345:Drug Industry / Q000191:economics / Q000379:methods* / Q000592:standards; D015713:Duplicate Publications as Topic; D005607:Fraud; D006801:Humans; D001523:Mental Disorders / Q000188:drug therapy; D018579:Patient Selection; D010506:Periodicals as Topic / Q000592:standards; D010818:Practice Patterns, Physicians'; D011600:Psychopharmacology / Q000379:methods* / Q000458:organization & administration; D011619:Psychotropic Drugs / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D017594:Publication Bias; D012107:Research Design / Q000592:standards* / Q000706:statistics & numerical data; D012109:Research Support as Topic / Q000191:economics / Q000592:standards*; D016896:Treatment Outcome
D011619:Psychotropic Drugs